Leo Lithium (LLL) Q1 2025 TU earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2025 TU earnings summary
6 Jun, 2025Executive summary
Completed divestment of the Goulamina Lithium Project and distributed 17.2 cents per share to shareholders.
Strategic focus shifted to acquiring a new lithium asset and seeking re-quotation on the ASX.
Workforce rationalisation and associated one-off costs completed post-divestment.
Ongoing screening of lithium opportunities globally, with advanced discussions underway.
Financial highlights
Closing cash balance at 31 March 2025 was A$57.6 million, down from A$269.3 million at 31 December 2024.
Distributed A$207.2 million to shareholders, including an unfranked dividend of A$189.9 million and a capital return of A$17.3 million.
Interest income of A$2.4 million earned during the quarter.
One-off staff-related payments totaled A$2.0 million, with a net cost of A$1.2 million after joint venture contributions.
Outlook and guidance
If no acquisition is significantly progressed by Q3 2025, Tranche 2 funds (US$171.2 million) will be returned to shareholders in H2 2025.
Any major acquisition using Tranche 2 funds will require shareholder approval.
Ongoing engagement with multiple lithium asset owners; no transaction finalized yet.
Latest events from Leo Lithium
- US$177.6M received from asset sale; M&A progress to determine future capital return.LLL
Q2 2025 TU24 Jul 2025 - Screening lithium assets globally, with capital return and acquisitions prioritized for 2025.LLL
AGM 2025 Presentation1 Jul 2025 - US$342.7M Goulamina sale to Ganfeng advances, with distributions to shareholders in 2025.LLL
Q3 2024 TU13 Jun 2025 - MLBV stake sale for US$342.7M enables shareholder distributions in 2025.LLL
Q2 2024 TU13 Jun 2025 - Leo Lithium to divest Goulamina stake to Ganfeng, returning proceeds and future fees to shareholders.LLL
AGM 2024 Presentation13 Jun 2025 - Leo Lithium to sell Goulamina Project to Ganfeng for US$342.7M after resolving Mali dispute.LLL
H2 202313 Jun 2025 - Goulamina sale completed; major cash return to shareholders and acquisition focus ahead.LLL
Q4 20246 Jun 2025